Table 1 Baseline demographics and characteristics (mITT population).

From: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials

Parameter

Xanomeline/Trospium (n = 314)

Placebo (n = 326)

Age (years), mean ± SD

44.6 ± 10.7

43.7 ± 11.3

Sex, n (%)

 Male

 Female

233 (74.2)

81 (25.8)

250 (76.7)

76 (23.3)

Race, n (%)

 Asian

 Black

 Native Hawaiian or Other Pacific Islander

 White

 Other

4 (1.3)

225 (71.7)

1 (0.3)

83 (26.4)

1 (0.3)

2 (0.6)

221 (67.8)

1 (0.3)

98 (30.1)

4 (1.2)

Ethnicity, n (%)

 Hispanic or Latino

 Not Hispanic or Latino

 Not reported

47 (15.0)

265 (84.4)

2 (0.6)

34 (10.4)

291 (89.3)

1 (0.3)

Country, n (%)

 United States

 Ukraine

295 (93.9)

19 (6.1)

300 (92.0)

26 (8.0)

Weight (kg), mean ± SD

88.9 ± 18.5

87.3 ± 18.6

BMI (kg/m2), mean ± SD

29.2 ± 5.5

28.9 ± 5.4

PANSS total score, mean ± SD

97.5 ± 9.0

97.0 ± 8.9

PANSS positive subscale score, mean ± SD

26.6 ± 3.6

26.4 ± 3.4

PANSS negative subscale score, mean ± SD

22.7 ± 3.8

22.6 ± 4.0

PANSS Marder negative factor, mean ± SD

22.4 ± 4.5

22.3 ± 4.6

CGI-S score, mean ± SD

5.1 ± 0.6

5.0 ± 0.6

  1. BMI body mass index, CGI-S Clinical Global Impression–Severity, PANSS Positive and Negative Syndrome Scale.